SELP+ TEC:CD8+ T cell crosstalk associates with improved radiotherapy efficacy in cervical cancer
- PMID: 39901166
- PMCID: PMC11789365
- DOI: 10.1186/s12943-025-02244-7
SELP+ TEC:CD8+ T cell crosstalk associates with improved radiotherapy efficacy in cervical cancer
Abstract
P-selectin (SELP) expression in tumor cells has been implicated in promoting tumor progression and treatment resistance across various cancers. However, our prior study identified SELP expression in a specific subpopulation of endothelial cells within cervical cancer (CC) and potentially linked to anti-cancer immune response. The precise mechanisms by which SELP influences anti-cancer immunity and its involvement in radiotherapy response in CC, however, remain elusive. To address these gaps, this study analyzed tumor tissue samples from 205 CC patients undergoing radiotherapy, scRNA-seq data from 42,159 cells of eight patients, and bulk RNA-sequencing data from 187 radiotherapy-treated patients. The results revealed that elevated SELP expression in tumor endothelial cells (TECs) was significantly correlated with improved survival outcomes in patients treated with radiotherapy. The SELPhigh group exhibited a prominent enrichment of immune-related pathways, coupled with a diminished enrichment in epithelial cell proliferation and angiogenesis pathways. Notably, this group demonstrated increased infiltration of CD8+ T cells and enhanced expression of chemokine receptors, including ACKR1. Furthermore, our data suggest that SELP+ TECs engage in crosstalk with CD8+ T cells via the ACKR1-CCL5 axis, which is associated with improved radiotherapy efficacy. In conclusion, these findings underscore the pivotal role of SELP+ TEC:CD8+ T cell interactions through the ACKR1-CCL5 pathway in enhancing radiotherapy response in CC. Targeting this crosstalk may offer novel therapeutic strategies to mitigate treatment resistance and improve patient survival.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The present study was approved by Shandong Cancer Hospital and Institute (Jinan, China). All patients provided written informed consent. Consent for publication: All the authors have read and approved the final manuscript for publication. Competing interests: The authors declare no competing interests.
Figures


References
-
- Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. - PubMed
-
- Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43. - PubMed
-
- Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):72–83. - PubMed
-
- Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA. 2007;298:2289–95. - PubMed
-
- Yeini E, Satchi-Fainaro R. The role of P-selectin in cancer-associated thrombosis and beyond. Thromb Res. 2022;213(Suppl 1):S22-s28. - PubMed
MeSH terms
Substances
Grants and funding
- 82272753/National Natural Science Foundation of China
- 82403773/National Natural Science Foundation of China
- ZR2021LZL002/Shandong Provincial Natural Science Foundation
- ZR2021QH006/Shandong Provincial Natural Science Foundation
- flzh202103/Bethune Cancer Radiotherapy Translational Medicine Research Fund
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous